<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04928222</url>
  </required_header>
  <id_info>
    <org_study_id>SKNJCT-002</org_study_id>
    <nct_id>NCT04928222</nct_id>
  </id_info>
  <brief_title>Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)</brief_title>
  <official_title>A Trial to Evaluate Placebo Microneedle Arrays in Healthy Human Volunteers (Part I), Followed by Proof of Concept Testing of Efficacy and Safety of Doxorubicin Microneedle Arrays in Subjects With Basal Cell Cancer (Part II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SkinJect, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SkinJect, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part I is designed as a study of P-MNA application in healthy human volunteers. The goal of&#xD;
      Part I is to determine several factors possibly affecting the rate and extent of microneedle&#xD;
      array dissolution, such as anatomic location; age; duration of array exposure to the skin;&#xD;
      and the criticality of proper array application to the skin. Part II will be a randomized&#xD;
      study in which doxorubicin-containing arrays will be applied to subjects demonstrated by&#xD;
      biopsy to have basal cell cancer. A subject will be randomized to one of four dose groups:&#xD;
      placebo microneedle array and 50 µg, 100 µg, and 200 µg doses of doxorubicin in a tip-loaded,&#xD;
      dissolvable microneedle arrays (D-MNA).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Investigational product will have randomly generated product code on label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with Eradication of Basal Cell Cancer based on Histologic Analysis</measure>
    <time_frame>Up to 4 weeks after the last array application to a subject</time_frame>
    <description>Tissue will be excised and sectioned for histologic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with dose-limiting toxicity and treatment-related adverse events by CTCAE v4.0</measure>
    <time_frame>Assessment at week 2 of subject visit</time_frame>
    <description>Determination of cutaneous tolerability of arrays after application</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Basal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Placebo-containing MNA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo-containing array will be applied to subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxorubicin-containing MNA - 50 µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A doxorubicin-containing array of 50 µg will be applied to subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxorubicin-containing MNA - 100 µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A doxorubicin-containing array of 100 µg will be applied to subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxorubicin-containing MNA - 200 µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A doxorubicin-containing array of 200 µg will be applied to subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo MNA for Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Training phase for application of arrays</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Doxorubicin-containing MNA</intervention_name>
    <description>A 15 square millimeter array containing 400 dissolvable microneedles delivering active agent</description>
    <arm_group_label>Doxorubicin-containing MNA - 100 µg</arm_group_label>
    <arm_group_label>Doxorubicin-containing MNA - 200 µg</arm_group_label>
    <arm_group_label>Doxorubicin-containing MNA - 50 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-containing MNA</intervention_name>
    <description>A 15 square millimeter array containing 400 dissolvable microneedles containing placebo</description>
    <arm_group_label>Placebo MNA for Training</arm_group_label>
    <arm_group_label>Placebo-containing MNA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult males and females, 18+ years in general good health as assessed by the&#xD;
             investigator.&#xD;
&#xD;
          2. Clinical laboratory results within the following ranges:&#xD;
&#xD;
               1. granulocytes ≥2,000/mm3&#xD;
&#xD;
               2. platelets &gt;50,000/mm3&#xD;
&#xD;
               3. serum creatinine ≤2X the upper limit of normal (ULN)&#xD;
&#xD;
               4. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate&#xD;
                  dehydrogenase (LDH), alkaline phosphatase ≤3X the ULN.&#xD;
&#xD;
          3. Subject must have no other &quot;clinically significant&quot; abnormal findings in his/her&#xD;
             medical history, physical examination or clinical laboratory test results as assessed&#xD;
             by the investigator.&#xD;
&#xD;
          4. Subject must be willing to adhere to the instructions of the investigator and his or&#xD;
             her research team.&#xD;
&#xD;
          5. Subject must sign an Informed Consent Form prior to any study specific procedures and&#xD;
             entry into the study.&#xD;
&#xD;
          6. BCC (subtype: superficial or nodular) confirmed histologically by diagnostic shave&#xD;
             biopsy at the Screening Visit. If previously confirmed, subjects can only have&#xD;
             diagnosed BCC via shaved biopsy within 6 months of first study treatment.&#xD;
&#xD;
          7. Biopsy removed ≤25% of the original volume of the target lesion.&#xD;
&#xD;
          8. Primary BCC (i.e., no previous treatment)&#xD;
&#xD;
          9. Lesion size ≥ 64 mm2 or 8 x 8 mm and ≤ 169 mm2 or 13 x 13 mm, i.e., the entire lesion&#xD;
             must be covered by 13X13 mm area of the array containing the microneedles&#xD;
&#xD;
         10. Subjects must avoid sunlight/ultraviolet light to the target lesion for the duration&#xD;
             of the study.&#xD;
&#xD;
         11. Female subjects must be:&#xD;
&#xD;
               1. postmenopausal (no menstrual period for a minimum of 12 months), or&#xD;
&#xD;
               2. surgically sterile upon entry into the study.&#xD;
&#xD;
               3. female subjects of childbearing potential must have a negative pregnancy test&#xD;
                  upon entry into this study and agree to use a highly effective method of&#xD;
                  contraception from Screening until the final follow-up visit. Consult Section 5.5&#xD;
                  in this protocol for a description of effective contraceptive methods. Female&#xD;
                  subjects must also have negative pregnancy tests before each dose is applied to&#xD;
                  female subjects&#xD;
&#xD;
         12. Male subjects with female partners of child bearing potential must be either&#xD;
             surgically sterile or agree to use a double-barrier contraception method (i.e., condom&#xD;
             + diaphragm, condom or diaphragm + spermicidal gel or foam) from screening until the&#xD;
             final follow-up visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of clinically significant, unstable medical conditions as assessed by the&#xD;
             investigator.&#xD;
&#xD;
          2. Previously demonstrated sensitivity to doxorubicin or carboxymethyl cellulose.&#xD;
&#xD;
          3. Female subjects who are pregnant or breastfeeding.&#xD;
&#xD;
          4. The subject has uncontrolled, significant intercurrent or recent illness.&#xD;
&#xD;
          5. Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin&#xD;
             inhibitors (e.g. dabigatran), betrixaban, or platelet inhibitors (eg, clopidogrel).&#xD;
             Prophylactic use of Low-dose aspirin for cardio-protection (per local applicable&#xD;
             guidelines) and low-dose low molecular weight heparins (LMWH) are permitted.&#xD;
&#xD;
          6. Topical therapy(ies) to the target lesion within 6 weeks of first treatment.&#xD;
&#xD;
          7. Prior excisional surgery performed on the lesion to be treated in this study.&#xD;
&#xD;
          8. Recent therapy(ies) to the BCC treatment area.&#xD;
&#xD;
          9. Recurrent BCC (previously treated) at the site presented for treatment.&#xD;
&#xD;
         10. BCC lesion to be treated is located in an area where excisional biopsy is undesired or&#xD;
             aesthetically unacceptable to the subject&#xD;
&#xD;
         11. Subject with other active malignancies except for non-metastatic prostate cancer,&#xD;
             carcinoma in situ of the skin or cervix, and basal cell cancer in locations other than&#xD;
             lesion of interest.&#xD;
&#xD;
         12. Subject with evidence of metastatic malignancies.&#xD;
&#xD;
         13. Concomitant disease requiring systemic immunosuppressive treatment.&#xD;
&#xD;
         14. Genetic skin cancer disorder, e.g., basal cell nevus syndrome.&#xD;
&#xD;
         15. Subject is currently participating or has participated in a study of an&#xD;
             investigational agent or has used an investigational device within 4 weeks prior to&#xD;
             the first dose of study treatment (patients who are in a follow-up phase of an&#xD;
             investigational study may participate as long as it has been 30 days after the last&#xD;
             dose of the previous investigational agent).&#xD;
&#xD;
         16. Evidence of dermatological disease or confounding skin condition within 3 mm margin of&#xD;
             the target BCC lesion, e.g., SCC, actinic keratosis, rosacea, psoriasis, atopic&#xD;
             dermatitis, eczema.&#xD;
&#xD;
         17. Existing condition or treatment within 3 months prior to the Screening Visit that may&#xD;
             have impact on clinical outcome for the treatment of BCC or delay in wound healing&#xD;
             from the standard of care excision.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan M Buttler</last_name>
    <role>Study Director</role>
    <affiliation>SkinJect, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael J Fare</last_name>
    <phone>2035332050</phone>
    <email>mfare@skinjectpatch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan M Buttler</last_name>
    <email>sbuttler@skinjectpatch.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beer Dermatology</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Dunn, RN, BSN</last_name>
      <phone>561-655-9055</phone>
      <email>mdunn@beerdermatology.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Basal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
    <mesh_term>Neoplasms, Basal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

